CADTH has undertaken an internal review of our processes for drugs and devices and established a revised process for the review of cell and gene therapies that leverages the strengths of both programs...

Managing Health Technologies: Supporting Appropriate, Affordable, and Accessible Care Every year, the effective management of health technologies grows more challenging. The number and complexity of...

The Pharmaceutical Advisory Committee Formulary Working Group for Health Technology Assessments (FWG-HTA) includes representatives from the federal, provincial, and territorial health ministries, and...

CADTH seeks patient perspectives to improve the quality of our assessments of medical procedures, devices, and drugs. Patients, families, and communities can offer insight on the diversity of...

Member — Jurisdictional (Atlantic Provinces) Jeannine Lagassé is Deputy Minister of Health and Wellness, Province of Nova Scotia. Jeannine joined the Nova Scotia civil service in1998. Prior to her...

For the purpose of Drug Reimbursement Reviews, a patient group is an organized group that represents patients with a specific disease or condition, or collection of diseases or conditions. Any...

Once Health Canada has approved a drug for use in Canada, the country’s public drug programs and cancer agencies must decide if the drug will be eligible for public reimbursement. The CADTH drug...

CADTH's reimbursement review processes are meant to reduce duplication across jurisdictions, maximize the use of limited resources, and enhance the consistency of drug reviews. CADTH undertakes...

Patient Input and Feedback CADTH seeks patients’ perspectives to improve the relevance and quality of our reviews. Also, to enable those possibly affected by the reviews to have an opportunity to...

The table below provides a list of the participating drug programs and other agencies that partner with CADTH. For contact information and required documentation when applying for reimbursement from...